(Q37933855)

25 August 2017

1 reference

title

EGFR-targeted therapy (English)

1 reference

25 August 2017

3

1 reference

25 August 2017

5

Sabine Tejpar

0 references

Bart C Jacobs

series ordinal

2

object named as

Bart Jacobs

1 reference

25 August 2017

4

Fortunato Ciardiello

1 reference

25 August 2017

Loredana Vecchione

1

1 reference

PubMed ID

21925171

25 August 2017

language of work or name

English

0 references

publication date

7 September 2011

1 reference

Experimental Cell Research

25 August 2017

1 reference

25 August 2017

317

1 reference

25 August 2017

2765-2771

1 reference

25 August 2017

19

1 reference

EGFR antagonists in cancer treatment

25 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.08.021

ERBBs in the gastrointestinal tract: recent progress and new perspectives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.08.021

Estimates of the cancer incidence and mortality in Europe in 2006.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.08.021

Urgent need for a new staging system in advanced colorectal cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.08.021

Genetic alterations during colorectal-tumor development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.08.021

Colorectal cancer molecular biology moves into clinical practice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.08.021

The genomic landscapes of human breast and colorectal cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.08.021

The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.08.021

Untangling the ErbB signalling network

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.08.021

Importance of epidermal growth factor receptor signaling in establishment of adenomas and maintenance of carcinomas during intestinal tumorigenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.08.021

Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.08.021

Paneth cells constitute the niche for Lgr5 stem cells in intestinal crypts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.08.021

Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.08.021

Erlotinib in non-small cell lung cancer treatment: current status and future development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.08.021

Panitumumab, a monoclonal anti epidermal growth factor receptor antibody in colorectal cancer: another one or the one?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.08.021

Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.08.021

Cetuximab, a chimeric human mouse anti-epidermal growth factor receptor monoclonal antibody, in the treatment of human colorectal cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.08.021

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.08.021

Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.08.021

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.08.021

Prevalence of ras gene mutations in human colorectal cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.08.021

High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.08.021

Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.08.021

Hyperactive Ras in developmental disorders and cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.08.021

Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.08.021

Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.08.021

KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.08.021

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.08.021

KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.08.021

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.08.021

Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.08.021

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.08.021

Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.08.021

Moyamoya disease and moyamoya syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.08.021

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.08.021

KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.08.021

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.08.021

Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.08.021

PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.08.021

PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.08.021

PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.08.021

PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.08.021

Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.08.021

EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.08.021

Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.08.021

Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.08.021

Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.08.021

Pharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: biomarker analysis of a phase I dose-escalation study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.08.021

Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.08.021

Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.08.021

10.1016/J.YEXCR.2011.08.021

7 January 2021

Identifiers

DOI

1 reference

25 August 2017

1 reference

PubMed ID

21925171